Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd

• https://x.com/RichardPAConway/status/1983200333644902456/photo/1

Semaglutide isn’t just for weight loss? In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls. GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism. @RheumNow #ACR25 Abstract#2286

Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi in diabetic RA patients. V Tachy (HR 1.4), PPM need (HR 1.4) significantly higher. AF, SVT, VF all numerically increased. @RheumNow #ACR25 Abstr#2283 https://t.co/U2Tk38Mobg

• https://x.com/RichardPAConway/status/1983199326869565612/photo/1

Effect of air pollution in RA Prospective cohort 1000+pts w/ 12000+ visits Higher levels of pollution & specific size of particles PM25 asso w/ -10% higher odd of flare -Higher DAS CRP and CDAI Now the interesting pattern: PM25 exposure increases 3 weeks before flares https://t.co/MOskJzk05g

• https://x.com/AurelieRheumo/status/1983197971677053169/photo/1
• https://x.com/AurelieRheumo/status/1983197971677053169/photo/1

Higashida-Konishi et al. RA. Insomnia and fatigue in >80%, depression in 13%. RA disease activity is associated with depression, fatigue, and insomnia. @RheumNow #ACR25 Abstr#2254 https://t.co/7SibPW6BBw

• https://x.com/RichardPAConway/status/1983197816815333851/photo/1

Can AI predict who stops their RA meds? In older adults on b/tsDMARDs, interpretable ML found frailty, comorbidity & age top the list for nonadherence risk. @RheumNow #ACR25 Abstract#2287

Girolami et al. VA study. Safety of DMARDs in RA following melanoma. 644 patients. 3 year all cause mortality. No significant difference, but graph sure looks like b/tsDMARDs are better. No melanoma specific mortality/recurrence data however. @RheumNow #ACR25 Abstr#2237 #ACRBest https://t.co/IN4LDkioT7

• https://x.com/RichardPAConway/status/1983195049287352507/photo/1

Is RA-ILD associated with/ higher risk of infection? Retrospective US cohort study 151 RA-ILD 980 matched controls 79% higher risk of any and pulmonary infections in RA-ILD Pathogen type: bacterial, viral and fungi Some of these infections are preventable! Take Home: https://t.co/fPmRjLL7Po

• https://x.com/AurelieRheumo/status/1983194685536375134/photo/1
• https://x.com/AurelieRheumo/status/1983194685536375134/photo/1

A prediction model for RA-ILD in RA pts: is it possible? Not quite yet! Veterans Affairs RA registry 2700+ pts 5% of prevalent ILD Associated w/ -GDF-15 -Pentraxin 3 No prediction for Incident disease Needs more work to understand implications for practice @RheumNow #ACR25 https://t.co/CmW72nybcQ

• https://x.com/AurelieRheumo/status/1983191216347865510/photo/1
• https://x.com/AurelieRheumo/status/1983191216347865510/photo/1

#1724 MAIT cells central in RA pathogenesis. These innate-like T cells accumulate in synovial fluid, driving fibroblast activation, cytokine release & joint damage. Blocking MAIT activation or deleting MR1 reduces arthritis in mice- a potential new target in RA. @RheumNow #ACR25